Drugs · acquisition-cost intelligence
erythromycin
· ingredient erythromycinAntiinfectives for treatment of acne· ERYTHROMYCIN 5 mg/g
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per GM
$2.86
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per GM — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other erythromycin products, cheapest acquisition cost first. Per GM — confirm strength/form equivalence before switching.
| Product | NADAC / GM | vs this |
|---|---|---|
| erythromycin | $0.34583 | −$2.52 |
| Erythromycin | $0.66199 | −$2.20 |
| Ery | $1.24 | −$1.63 |
| E.E.S | $1.59 | −$1.27 |
| Erythromycin | $2.87 | +$0.00690 |
| Erythromycin | $2.97 | +$0.10980 |
| ERY-TAB | $2.97 | +$0.10980 |
| erythromycin | $5.96 | +$3.10 |
Medicare Part D coverage · CY2026
On 328 plan formularies · typical tier 2
Prior auth 0% · Step therapy 0% · Quantity limit 39% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.